Stock listing
NASDAQ:CDT CDT Equity Inc. Stock
Home listing (NASDAQ) of CDT Equity Inc.
Follow CDT Equity Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:CDT
$0.23 USD -0.04 (-13.9%)
Close on Nov 20, 2026
- Day range
- $0.223 – $0.245 USDNov 20, 2026
- Volume
- 853,743 sharesNov 20, 2026
- Market cap
- $234,109 USDAt the close on Nov 20, 2026 · price × 1.02M shares outstanding
- 52-week range
- $0.065 – $14,562.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $835,037 USDMedian day 23,705 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CDT · Home | $0.23 USD | -0.037 (-13.9%) | 853,743 | $0.234 | $0.245 | $0.223 | $0.267 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CDT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.23 | -0.037 | -13.9% | $0.234 | $0.245 | $0.223 | 853,743 | |
| $0.267 | -0.076 | -22.1% | $0.287 | $0.30 | $0.261 | 2,466,465 | |
| $0.343 | -0.017 | -4.7% | $0.355 | $0.36 | $0.322 | 224,469 | |
| $0.36 | -0.017 | -4.5% | $0.375 | $0.38 | $0.342 | 337,079 | |
| $0.377 | -0.023 | -5.8% | $0.416 | $0.417 | $0.351 | 299,190 | |
| $0.40 | -0.043 | -9.7% | $0.435 | $0.448 | $0.38 | 776,800 | |
| $0.443 | -0.067 | -13.1% | $0.495 | $0.503 | $0.44 | 518,700 | |
| $0.51 | -0.051 | -9.1% | $0.483 | $0.56 | $0.454 | 1,429,900 | |
| $0.561 | -0.279 | -33.2% | $0.77 | $0.77 | $0.561 | 944,400 | |
| $0.84 | -0.47 | -35.9% | $1.08 | $1.08 | $0.821 | 3,389,100 | |
| $1.31 | +0.47 | +56.0% | $1.38 | $1.61 | $0.981 | 27,133,000 | |
| $0.84 | -0.18 | -17.6% | $0.94 | $0.94 | $0.78 | 4,864,260 | |
| $1.02 | -0.32 | -23.9% | $1.00 | $1.02 | $0.94 | 319,540 | |
| $1.34 | -0.06 | -4.3% | $1.32 | $1.40 | $1.20 | 215,210 | |
| $1.40 | +1.332 | +1958.8% | $1.24 | $1.42 | $1.08 | 5,304,075 | |
| $0.068 | -0.009 | -11.7% | $0.068 | $0.07 | $0.065 | 269,745 | |
| $0.077 | -0.006 | -7.2% | $0.077 | $0.077 | $0.069 | 360,300 | |
| $0.083 | +0.003 | +3.8% | $0.09 | $0.092 | $0.066 | 7,765,980 | |
| $0.08 | -0.014 | -14.9% | $0.089 | $0.092 | $0.076 | 264,860 | |
| $0.094 | -0.036 | -27.7% | $0.119 | $0.119 | $0.09 | 347,870 | |
| $0.13 | 0.00 | 0.0% | $0.132 | $0.174 | $0.125 | 298,835 | |
| $0.13 | -0.015 | -10.3% | $0.141 | $0.144 | $0.128 | 109,175 | |
| $0.145 | -0.014 | -8.8% | $0.16 | $0.161 | $0.138 | 86,075 | |
| $0.159 | -0.027 | -14.5% | $0.174 | $0.178 | $0.145 | 95,810 | |
| $0.186 | -0.049 | -20.9% | $0.199 | $0.209 | $0.172 | 67,715 | |
| $0.235 | +0.026 | +12.4% | $0.20 | $0.242 | $0.192 | 593,400 | |
| $0.209 | -0.031 | -12.9% | $0.197 | $0.217 | $0.181 | 110,435 | |
| $0.24 | -0.21 | -46.7% | $0.243 | $0.252 | $0.195 | 1,117,330 | |
| $0.45 | -0.21 | -31.8% | $0.591 | $0.611 | $0.415 | 48,320 | |
| $0.66 | -0.058 | -8.1% | $0.702 | $0.713 | $0.631 | 18,250 | |
| $0.718 | -0.082 | -10.3% | $0.79 | $0.797 | $0.70 | 23,320 | |
| $0.80 | -0.036 | -4.3% | $0.821 | $0.851 | $0.796 | 13,155 | |
| $0.836 | -0.094 | -10.1% | $0.899 | $0.899 | $0.804 | 24,090 | |
| $0.93 | +0.012 | +1.3% | $0.90 | $0.94 | $0.851 | 45,915 | |
| $0.918 | -0.072 | -7.3% | $0.973 | $0.973 | $0.85 | 17,640 | |
| $0.99 | -0.26 | -20.8% | $1.28 | $1.28 | $0.95 | 51,270 | |
| $1.25 | -0.11 | -8.1% | $1.34 | $1.371 | $1.22 | 12,955 | |
| $1.36 | -0.09 | -6.2% | $1.45 | $1.556 | $1.34 | 16,360 | |
| $1.45 | -0.45 | -23.7% | $1.87 | $1.884 | $1.44 | 29,990 | |
| $1.90 | -0.10 | -5.0% | $1.875 | $1.925 | $1.70 | 2,439 | |
| $2.00 | -1.025 | -33.9% | $2.20 | $2.225 | $1.975 | 2,133 | |
| $3.025 | -0.35 | -10.4% | $3.025 | $3.175 | $3.00 | 592 | |
| $3.375 | -0.175 | -4.9% | $3.45 | $3.60 | $3.275 | 932 | |
| $3.55 | -0.30 | -7.8% | $3.75 | $3.75 | $3.25 | 1,001 | |
| $3.85 | -0.50 | -11.5% | $4.15 | $4.25 | $3.825 | 358 | |
| $4.35 | -0.40 | -8.4% | $4.025 | $4.425 | $3.925 | 1,446 | |
| $4.75 | -0.20 | -4.0% | $5.15 | $5.15 | $4.50 | 322 | |
| $4.95 | -0.125 | -2.5% | $5.175 | $5.20 | $4.625 | 381 | |
| $5.075 | -0.40 | -7.3% | $5.30 | $5.425 | $4.825 | 460 | |
| $5.475 | -0.775 | -12.4% | $5.50 | $5.675 | $5.225 | 434 | |
| $6.25 | -2.375 | -27.5% | $6.425 | $6.45 | $5.75 | 816 | |
| $8.625 | -6.375 | -42.5% | $10.30 | $10.30 | $8.125 | 3,572 | |
| $15.00 | -0.425 | -2.8% | $15.00 | $15.50 | $14.50 | 10 | |
| $15.42 | -0.20 | -1.3% | $15.00 | $16.60 | $14.55 | 26 | |
| $15.63 | -3.10 | -16.6% | $18.25 | $18.63 | $15.30 | 59 | |
| $18.72 | -4.025 | -17.7% | $22.00 | $22.15 | $17.50 | 61 | |
| $22.75 | -14.25 | -38.5% | $28.75 | $30.00 | $22.50 | 104 | |
| $37.00 | -5.00 | -11.9% | $42.50 | $42.75 | $35.00 | 219 | |
| $42.00 | -0.25 | -0.6% | $42.75 | $44.75 | $40.00 | 11 | |
| $42.25 | -4.75 | -10.1% | $49.50 | $50.75 | $40.50 | 39 | |
| $47.00 | -0.25 | -0.5% | $47.25 | $49.25 | $45.00 | 12 | |
| $47.25 | -4.00 | -7.8% | $52.75 | $52.75 | $45.50 | 7 | |
| $51.25 | -11.00 | -17.7% | $60.25 | $61.25 | $48.00 | 40 | |
| $62.25 | -9.25 | -12.9% | $73.75 | $74.50 | $61.50 | 5 | |
| $71.50 | -1.00 | -1.4% | $74.75 | $85.00 | $71.00 | 6 | |
| $72.50 | -2.75 | -3.7% | $74.00 | $75.25 | $70.50 | 2 |
Splits
6 splits since 2025 · NASDAQ:CDT · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-25 | Consolidation | |
| 1-for-10 | Consolidation | |
| 1-for-25 | Consolidation | |
| 1-for-8 | Consolidation | |
| 1-for-15 | Consolidation | |
| 1-for-100 | Consolidation |
- Ticker
- NASDAQ:CDT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
CDT Notes Sarborg’s Sale of Cryptocurrency Trading Agent
Latest news
CDT Notes Sarborg’s Sale of Cryptocurrency Trading Agent
Nov 19, 2026
Closed $0.267 (-22.1%) on Nov 19, 2026
CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo
Nov 11, 2026
Closed $0.51 (-9.1%) on Nov 11, 2026
CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
Oct 30, 2026
Closed $0.068 (-11.7%) on Oct 30, 2026
CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch
Oct 27, 2026
Closed $0.08 (-14.9%) on Oct 27, 2026
CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset
Oct 14, 2026
Closed $0.24 (-46.7%) on Oct 14, 2026
CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
Sep 29, 2026
Closed $1.45 (-23.7%) on Sep 29, 2026
CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
Sep 18, 2026
Closed $4.35 (-8.4%) on Sep 18, 2026
CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
Sep 10, 2026
Closed $8.63 (-42.5%) on Sep 10, 2026
CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
Sep 2, 2026
Closed $22.75 (-38.5%) on Sep 2, 2026
CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
Sep 1, 2026
Closed $37.00 (-11.9%) on Sep 1, 2026
CDT Equity Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 28 in the last 12 months · 66 in all · newest Nov 19, 2026 · oldest 2022
- Decks
- 2 decks · latest Jul 21, 2023
Where CDT Equity Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CDT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:CDT | BOATS | United States | USD |
| Frankfurt:ZK7 | Frankfurt | Germany | EUR |
Valuation
Price/book 0.0× against a median of 0.2×: the lowest of 5 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$1.49M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.14
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| Jaguar Health, Inc. · NASDAQ:JAGX | US$527,406 | −US$1.48M | n/a | −0.1× | n/a | 0.0× | −181.8% | 0.2× | 3.75 |
| Altamira Therapeutics Ltd. · OTC:CYTOF | US$404,655 | US$400,900 | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.64 |
| NKGen Biotech Inc. · OTC:NKGN | US$391,807 | US$38.58M | n/a | n/a | n/a | n/a | n/a | n/a | 0.88 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,522 | −US$4,071 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| Median of the others | US$278,926 | US$73,510 | 1.2× | 0.3× | 0.2× | −262.8% | 0.1× | 1.20 |
Team and board
Officers
| Officer | Role |
|---|---|
| James Bligh | Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Ulrik Olsen | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 | −10.0% |
| Q2 2026 | Aug 12, 2026 | +6.3% |
| Q1 2026 | Jun 25, 2026 | −41.6% |
| Q3 2025 | Nov 12, 2025 · After close | −7.2% |
| Q2 2025 | Aug 14, 2025 · After close | 0.0% |
| Q1 2025 | May 15, 2025 | 0.0% |
| Q4 2024 | Mar 28, 2025 | 0.0% |
| Q4 2022 | Mar 28, 2023 | 0.0% |
| Q3 2022 | Nov 7, 2022 | 0.0% |
| Q2 2022 | Aug 11, 2022 | 0.0% |
All 11 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2022 | May 18, 2022 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Murphy Canyon Acquisition — SPAC Merger (July 2023) | SPAC merger | 30 slides | Jul 21, 2023 |
| Conduit Pharmaceuticals — SPAC Merger (November 2022) | SPAC merger | 29 slides | Nov 8, 2022 |
IPO
Withdrawn on Jan 26, 2022. Filed with the SEC to go public on Jan 6, 2022, as Murphy Canyon Acquisition Corp., a blank check company (SPAC).
- Price
- US$10.00 a unit
- Units offered
- 11,500,000 units
- Offering size
- US$115 million
- Underwriters' option
- Up to 1,725,000 more units
- Listing
- MURFU on the Nasdaq Global Market
- Underwriters
- A.G.P., The Benchmark Company, LLC · In the order on the cover
- Units delivered
- On or about Feb 7, 2022
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 9, 2021 |
| Filed publicly | Jan 6, 2022 |
| Amended once | Jan 28, 2022 |
| Filing withdrawn | Jan 26, 2022 |
Filings
| Filing | Filed |
|---|---|
| 424B5 · Prospectus | Feb 4, 2022 |
| EFFECT · Notice that a registration is effective | Feb 2, 2022 |
| CORRESP · Letter to the SEC | Feb 1, 2022 |
| CORRESP · Letter to the SEC | Feb 1, 2022 |
| S-1/A · Registration statement, amended | Jan 28, 2022 |
| CORRESP · Letter to the SEC | Jan 26, 2022 |
| RW · Request to withdraw a registration | Jan 26, 2022 |
| CERT · Exchange's certificate of listing | Jan 25, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 24, 2022 |
| CORRESP · Letter to the SEC | Jan 21, 2022 |
All 14 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jan 21, 2022 |
| S-1 · Registration statement | Jan 6, 2022 |
| UPLOAD · Letter from the SEC | Dec 20, 2021 |
| DRS · Draft registration statement | Dec 9, 2021 |
Open IPO · From the cover of the final prospectus (424B5) filed Feb 4, 2022
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.72B | 922.2M | 0 | 0 | 0 |
| Cost of revenue | 1.68B | 457.0K | |||
| Gross profit | 1.03B | -457.0K | |||
| Research and development | 5.05M | 3.38M | 90.0K | 37.0K | 283.0K |
| Selling, general and administrative | 31.7M | 12.0M | 5.17M | 3.05M | 2.89M |
| Operating income | -36.8M | -15.4M | -5.26M | -3.16M | -3.17M |
| Depreciation and amortization | 2.42M | 10.0K | 0 | 1.73M | 484.0K |
| EBITDA | -34.3M | -15.4M | -5.26M | -1.43M | -2.69M |
| Interest expense | 200.0K | 32.0K | 0 | 100.0K | |
| Income before tax | -39.2M | -17.8M | -536.0K | 773.5K | -3.66M |
| Income tax | 29.3M | -29.5M | -168.0K | 374.9K | 247.4K |
| Net income | -39.2M | -17.8M | -535.0K | -4.89M | -3.66M |
| Earnings per share, basic | -1,177.89 | -61,598.62 | -0.79 | -0.13 | |
| Earnings per share, diluted | -1,177.89 | -61,598.62 | -8.92 | -0.13 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | 1.51M | 554.0K | 4.23M | 345.8K | 48.6K |
| Short-term investments | 600.0K | 4.20M | |||
| Receivables | 462.8M | 489.0K | |||
| Inventory | 402.3M | 343.1M | |||
| Current assets | 4.38M | 2.71M | 5.73M | 646.6K | 104.2K |
| Property, plant and equipment | 269.0K | 40.0K | |||
| Goodwill | 1.04B | 1.02B | |||
| Total assets | 5.65M | 4.19M | 7.22M | 5.00K | 213.1K |
| Accounts payable | 1.91M | 1.43M | 215.0K | 0 | |
| Current liabilities | 12.8M | 10.7M | 1.80M | 4.18M | 192.5K |
| Long-term debt | 2.01M | 749.0K | |||
| Total debt | 1.29B | 7.46M | 985.0K | 2.01M | 177.1K |
| Total liabilities | 12.8M | 11.0M | 7.68M | 10.1M | 192.5K |
| Shareholders' equity | -7.17M | -6.79M | -457.0K | -10.1M | 20.6K |
| Shares outstanding | 18 | 461 | 738.3K | 64.6M | 240 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash from operations | -15.6M | -9.68M | -7.72M | -2.27M | -2.15M |
| Capital spending | -2.40M | -51.0K | 0 | 0 | -5 |
| Free cash flow | -18.0M | -9.73M | -7.72M | -2.27M | -2.15M |
| Cash from investing | -808.0K | -43.0K | 725.0K | -183.0K | 48.6K |
| Cash from financing | 17.4M | 6.07M | 10.9M | 2.45M | 1.90M |
| Dividends paid | -7.97M | -8.20M | |||
| Share buybacks | -106.0K | 0 | |||
| Change in cash | 955.0K | -3.67M | 4.23M | 297.2K | -252.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 424B3 · Prospectus | Nov 17, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 424B3 · Prospectus | Nov 16, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 16, 2026 | Meeting outcome | SEC |
| 424B3 · Prospectus | Nov 9, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 6, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 4, 2026 | Offer document | SEC |
| 8-K · Current report | Nov 4, 2026 | Current report | SEC |
| 424B3 · Prospectus | Nov 3, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Oct 27, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Oct 27, 2026 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Oct 27, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 27, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 27, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Oct 16, 2026 | Meeting notice | SEC |
| 424B3 · Prospectus | Oct 13, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 13, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 8, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Oct 2, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 25, 2026 | Current report | SEC |
| 424B3 · Prospectus | Sep 18, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 18, 2026 | Material contract | SEC |
| 424B3 · Prospectus | Sep 18, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 18, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 9, 2026 | Big-stake notice | SEC |
| S-1 · Registration statement | Sep 8, 2026 | Offer document | SEC |
| 8-K · Current report | Sep 4, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 1, 2026 | Current report | SEC |
| 8-K · Current report | Sep 1, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 21, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 21, 2026 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Aug 21, 2026 | Current report | SEC |
| 8-K/A · Current report, amended | Aug 21, 2026 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Aug 12, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Aug 11, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 11, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 6, 2026 | Material contract | SEC |
| 8-K/A · Current report, amended | Aug 3, 2026 | Acquisition or disposal | SEC |
| PRE 14A · Preliminary proxy statement | Jul 31, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 31, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 29, 2026 | Financing | SEC |
| 8-K · Current report | Jul 16, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Jul 15, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 7, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 29, 2026 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 23, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 28, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 20, 2026 | Big-stake notice | SEC |
| NT 10-Q · Late filing notice | May 15, 2026 | Explanation request | SEC |
| 8-K · Current report | May 15, 2026 | Material contract | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | May 4, 2026 | Other filings | SEC |
| 424B3 · Prospectus | May 1, 2026 | Offer document | SEC |
| 3 · Initial statement of ownership | Apr 30, 2026 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Apr 30, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 29, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 27, 2026 | Management or board change | SEC |
| S-3 · Registration statement | Apr 21, 2026 | Offer document | SEC |
| 10-K · Annual report | Apr 15, 2026 | Annual report | SEC |
| 424B5 · Prospectus | Apr 2, 2026 | Offer document | SEC |
| NT 10-K · Late filing notice | Apr 1, 2026 | Explanation request | SEC |
| 4 · Change in ownership | Mar 30, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 30, 2026 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Mar 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 25, 2026 | Current report | SEC |
| 8-K · Current report | Mar 18, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Mar 9, 2026 | Material contract | SEC |
| DEF 14A · Proxy statement | Mar 6, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 24, 2026 | Material contract | SEC |
| PRE 14A · Preliminary proxy statement | Feb 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Feb 23, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 18, 2026 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 10, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 10, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 6, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jan 30, 2026 | Offer document | SEC |
| S-3 · Registration statement | Jan 29, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 22, 2026 | Material contract | SEC |
| 8-K · Current report | Jan 2, 2026 | Material contract | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 22, 2025 | Big-stake notice | SEC |
| S-8 POS | Dec 12, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 12, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 9, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 22, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 26, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 18, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Current report | SEC |
| 424B3 · Prospectus | Aug 12, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Aug 11, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 8, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Aug 8, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 5, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 5, 2025 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 31, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | Jul 31, 2025 | Offer document | SEC |
| DEF 14A · Proxy statement | Jul 9, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Jul 8, 2025 | Annual report | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 3, 2025 | Current report | SEC |
| 8-K · Current report | May 16, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2025 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | May 7, 2025 | Insider trade | SEC |
| 8-K · Current report | May 6, 2025 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 28, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 28, 2025 | Other filings | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2025 | Current report | SEC |
| S-3 · Registration statement | Apr 22, 2025 | Offer document | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 16, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 4, 2025 | Material contract | SEC |
| 8-K/A · Current report, amended | Apr 2, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Apr 1, 2025 | Current report | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 424B5 · Prospectus | Mar 10, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 6, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 20, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Feb 19, 2025 | Current report | SEC |
| 424B5 · Prospectus | Feb 19, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Feb 14, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 13, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 11, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 11, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 11, 2025 | Current report | SEC |
| 424B5 · Prospectus | Feb 10, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Feb 6, 2025 | Offer document | SEC |
| S-3 · Registration statement | Feb 5, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 23, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Jan 15, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 14, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 20, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Dec 17, 2024 | Material contract | SEC |
| 424B3 · Prospectus | Dec 16, 2024 | Offer document | SEC |
| DEF 14A · Proxy statement | Dec 9, 2024 | Meeting notice | SEC |
| 424B3 · Prospectus | Dec 9, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Dec 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 4, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Dec 2, 2024 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Nov 26, 2024 | Meeting notice | SEC |
| S-3 · Registration statement | Nov 25, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 25, 2024 | Material contract | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 19, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 14, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Nov 4, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Nov 4, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 4, 2024 | Other filings | SEC |
| DEFA14A · Additional proxy material | Nov 1, 2024 | Meeting notice | SEC |
| 8-K · Current report | Nov 1, 2024 | Material contract | SEC |
| CORRESP · Letter to the SEC | Oct 31, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 29, 2024 | Other filings | SEC |
| ARS · Annual report to shareholders | Oct 28, 2024 | Annual report | SEC |
This page holds 200 of 375 filings. Open Filings
Cap table
Built by 6ix from CDT Equity Inc.’s releases
- Common shares
- 1,017,864
- Fully diluted
- 1,017,864
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,017,864 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,017,864 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Knuettel Francis II Other companies: OS Therapies Incorporated (Chief Financial Officer · Since at least Nov 10, 2026); Splash Beverage Group, Inc. (nv) (Director · Since at least Apr 27, 2026); Beeline Holdings, Inc. (Director · Since at least May 14, 2025); Pelthos Therapeutics Inc. (CFO, Treas & Secty · Since at least Feb 15, 2024); Tevogen Bio Holdings Inc. (Chief Financial Officer · Jun 7, 2023 – Jun 7, 2023 · Past); Oceantech Acquisitions I Corp (Chief Financial Officer · Mar 13, 2023 – Mar 13, 2023 · Past); Forum Markets, Incorporated (Director · Jul 2, 2021 – Sep 4, 2023 · Past); Unrivaled Brands Inc (CEO and President, Director · Jun 7, 2021 – Jun 18, 2021 · Past); SCWorx Corp. (Director · Feb 1, 2019 – Nov 26, 2019 · Past); Aqua Metals, Inc. (Chief Financial Officer · May 9, 2018 – Jun 15, 2018 · Past); Spindle Inc (Director · Oct 21, 2015 – Jun 30, 2017 · Past); MARA Holdings, Inc. (CHIEF FINANCIAL OFFICER · May 15, 2014 – Nov 3, 2014 · Past) | Director · Feb 2, 2022 – Feb 2, 2022 · Past |
| Freda Lewis-Hall Other companies: Pyxis Oncology, Inc. (Director · Since at least Oct 7, 2021); SpringWorks Therapeutics Inc (Director · Since at least Mar 29, 2019); EXACT Sciences Corporation (Director · Apr 22, 2020 – Jun 8, 2023 · Past); 1Life Healthcare Inc (Director · Jan 30, 2020 – Feb 22, 2023 · Past); Pfizer, Inc. (Executive Vice President · Feb 22, 2018 – Feb 27, 2019 · Past) | Director · Since at least Sep 22, 2023 |
| Faith L. Charles Other companies: CNS Pharmaceuticals, Inc. (Chair · Since at least Dec 30, 2022); Avenue Therapeutics, Inc. (Director · Since at least May 16, 2022); Abeona Therapeutics Inc. (Interim Chair, Director · Since at least Mar 26, 2021) | Director · Sep 22, 2023 – Apr 16, 2025 · Past |
| Adam Sragovicz Other companies: Intellicheck, Inc. (Chief Financial Officer · Since at least Aug 1, 2024); Presidio Property Trust, Inc. (Chief Financial Officer · Jan 11, 2018 – Jan 3, 2023 · Past) | Chief Financial Officer · Feb 2, 2022 – May 15, 2024 · Past |
| Chele Chiavacci Farley Other companies: General Purpose Acquisition Corp. (Director · Since at least Dec 2, 2025) | Director · Since at least Feb 2, 2022 |
| Jack Kendrick Heilbron Other companies: Presidio Property Trust, Inc. (Chief Executive Officer, Director · Since at least Feb 27, 2008) | CEO, President, and Chairman, Director · Feb 2, 2022 – Feb 2, 2022 · Past |
| Jennifer Isacoff McNealey Other companies: Viskase Holdings, Inc. (Director · Sep 25, 2013 – Sep 25, 2013 · Past) | Director · Sep 22, 2023 – May 13, 2024 · Past |
| Andrew Regan | Chief Executive Officer, Director · Since at least Sep 22, 2023 |
| David Tapolczay | Chief Executive Officer, Director · Sep 22, 2023 – Nov 18, 2024 · Past |
| James Bligh | Chief Executive Officer · Since at least Sep 22, 2023 |
All 13 people
| Person | Seat |
|---|---|
| Richard Edward Feinberg | Director · Feb 2, 2022 – Feb 2, 2022 · Past |
| Simon Fry | Director · Since at least Nov 19, 2024 |
| Ulrik Olsen | Board Member · Since at least Apr 27, 2026 |
Log in to ask 6ix AI your own questions about CDT Equity Inc.